Healthcare Executives Embrace Generative AI to Boost Patient Outcomes
Healthcare executives are increasingly adopting generative AI, with 90% reporting positive ROI from their investments. The Global AI in Healthcare Market is projected to reach $164.16 billion by 2030, growing at a 49.1% CAGR. In a significant development, Avant Technologies has partnered with Roche and Salud 360 to launch a pilot program in Costa Rica targeting diabetic retinopathy using AI technology. The program utilizes non-mydriatic fundus cameras and AI to analyze retinal images for early detection of the condition. Initially implemented in Costa Rica, where diabetes affects 10.4% of adults, the program aims to expand to the US, Canada, and Europe if successful.
I dirigenti sanitari stanno sempre più adottando l'IA generativa, con il 90% di essi che riporta un ROI positivo dai loro investimenti. Si prevede che il Mercato Globale dell'IA in Sanità raggiunga $164,16 miliardi entro il 2030, con una crescita del 49,1% CAGR. In un importante sviluppo, Avant Technologies ha collaborato con Roche e Salud 360 per lanciare un programma pilota in Costa Rica che mira a trattare la retinopatia diabetica utilizzando la tecnologia dell'IA. Il programma utilizza fotocamere per fondo non midriatico e IA per analizzare le immagini retiniche al fine di rilevare precocemente la malattia. Inizialmente implementato in Costa Rica, dove il diabete colpisce il 10,4% degli adulti, il programma mira ad espandersi negli Stati Uniti, in Canada e in Europa se avrà successo.
Los ejecutivos de atención médica están adoptando cada vez más la IA generativa, con un 90% que reporta un ROI positivo de sus inversiones. Se proyecta que el Mercado Global de IA en Salud alcance $164.16 mil millones para 2030, creciendo a un CAGR del 49.1%. En un desarrollo significativo, Avant Technologies se ha asociado con Roche y Salud 360 para lanzar un programa piloto en Costa Rica enfocado en la retinopatía diabética usando tecnología de IA. El programa utiliza cámaras de fondo no midriático y IA para analizar imágenes de la retina con el fin de detectar tempranamente la condición. Inicialmente implementado en Costa Rica, donde el diabetes afecta al 10.4% de los adultos, el programa tiene como objetivo expandirse a EE. UU., Canadá y Europa si tiene éxito.
의료 경영진들이 생성적 AI를 점점 더 많이 채택하고 있습니다, 90%가 투자로부터 긍정적인 ROI를 보고하고 있습니다. 글로벌 헬스케어 AI 시장은 2030년까지 $164.16억에 이를 것으로 예상되며, 연평균 49.1% 성장할 것으로 보입니다. 중요한 발전으로, Avant Technologies는 Roche 및 Salud 360과 협력하여 AI 기술을 사용하여 당뇨병성 망막병증을 목표로 하는 파일럿 프로그램을 코스타리카에서 출시했습니다. 이 프로그램은 비산동 망막 카메라와 AI를 활용하여 망막 이미지를 분석하여 질환 조기 발견을 지원합니다. 당뇨병이 성인 10.4%에게 영향을 미치는 코스타리카에서 처음으로 시행된 이 프로그램은 성공할 경우 미국, 캐나다 및 유럽으로 확장할 계획입니다.
Les dirigeants du secteur de la santé adoptent de plus en plus l'IA générative, 90 % d'entre eux rapportant un retour sur investissement positif de leurs investissements. Le marché mondial de l'IA dans le secteur de la santé devrait atteindre 164,16 milliards de dollars d'ici 2030, avec une croissance de 49,1 % en moyenne annuelle. Dans un développement significatif, Avant Technologies a établi un partenariat avec Roche et Salud 360 pour lancer un programme pilote au Costa Rica ciblant la rétinopathie diabétique grâce à la technologie de l'IA. Le programme utilise des caméras de fond non mydriatiques et l'IA pour analyser les images rétiniennes afin de détecter la maladie à un stade précoce. Initialement mis en œuvre au Costa Rica, où le diabète touche 10,4 % des adultes, le programme vise à s'étendre aux États-Unis, au Canada et en Europe si cela s'avère fructueux.
Das Management im Gesundheitswesen nimmt zunehmend generative KI an, wobei 90 % einen positiven ROI aus ihren Investitionen berichten. Der globale Markt für KI im Gesundheitswesen wird voraussichtlich bis 2030 164,16 Milliarden US-Dollar erreichen und mit einer jährlichen Wachstumsrate von 49,1 % wachsen. In einer bedeutenden Entwicklung hat Avant Technologies eine Partnerschaft mit Roche und Salud 360 geschlossen, um ein Pilotprogramm in Costa Rica zu starten, das auf diabetische Retinopathie mit KI-Technologie abzielt. Das Programm nutzt nicht-mydratische Funduskameras und KI, um Netzhautbilder zur Früherkennung der Erkrankung zu analysieren. Zunächst in Costa Rica implementiert, wo Diabetes 10,4 % der Erwachsenen betrifft, zielt das Programm darauf ab, sich bei Erfolg auf die USA, Kanada und Europa auszuweiten.
- Global AI in Healthcare Market projected to reach $164.16B by 2030 with 49.1% CAGR
- 90% of healthcare executives report positive ROI from GenAI investments
- Strategic alliance formed between Avant Technologies, Roche, and Salud 360
- Potential for program expansion to US, Canada, and Europe markets
- None.
Insights
The strategic alliance between Avant Technologies, Roche and Salud 360 represents a significant development in AI-driven healthcare diagnostics. The pilot program targeting diabetic retinopathy in Costa Rica addresses a critical medical need, with
The projected
For NVIDIA, this healthcare AI trend represents a significant revenue opportunity as the company's hardware and frameworks like BioNeMo become essential infrastructure for AI-driven healthcare applications. The adoption by global pharmaceutical leaders and researchers positions NVIDIA to capture a substantial share of the rapidly growing healthcare AI market. The company's specialized healthcare division and targeted solutions like BioNeMo demonstrate strategic alignment with industry needs.
The partnership model demonstrated in the Avant-Roche-Salud 360 alliance showcases how smaller tech companies can leverage relationships with established healthcare players to accelerate market entry and validation. The potential expansion to US, Canadian and European markets through Ai-nova Acquisition Corp could create significant scaling opportunities.
Issued on behalf of Avant Technologies Inc.
The article continued: At Fortune's recent Brainstorm AI conference in
Avant Technologies' Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy
Avant Technologies, Inc. (OTCQB: AVAI), an emerging technology company developing solutions in artificial intelligence in healthcare, recently announced it has entered into a strategic alliance with global biotech giant Roche Holding AG (OTCQX: RHHBY, RHHVF), and leading pre-paid health plan provider Salud 360, to begin a pilot program to combat diabetic retinopathy using cutting-edge technology from Avant's partner Ainnova Tech, a leading healthcare technology company focused on revolutionizing early disease detection using AI.
Roche, Ainnova, and Salud 360 signed a strategic alliance to improve access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy using Ainnova's advanced technology and a patient-centered approach.
The pilot program will initially be implemented in
"At Roche, we are committed to timely diagnosis of diseases to improve clinical outcomes and thus contribute to the sustainability of the healthcare system," said, Alvaro Soto, General Manager of Roche
The pilot program will use non-mydriatic fundus cameras and artificial intelligence—developed by Ainnova Tech—to automatically analyze retinal images and identify microscopic changes in the retina. Such changes would be an early indicator of diabetic retinopathy without the need for invasive tests.
By implementing the pilot program in
The results of this pilot program will be the basis for developing the model beyond borders to benefit communities facing similar challenges in accessing medical care.
"We are proud to be able to put our technology at the service of a project that has the potential to prove itself as a massive impact model in early detection, and which we believe is replicable globally," said Vinicio Vargas, CEO of Ainnova Tech and member of AAC's Board of Directors. "Today, we are starting with diabetic retinopathy, but the vision is that we can eventually multiply this same effort for other critical diseases that require innovative solutions."
According to data from the Costa Rican Institute for Research and Teaching in Nutrition and Health (Inciensa), uncontrolled diabetes is the leading cause of preventable blindness in the country's adult population. To make matters worse, between
According to the World Health Organization,
Prior to the Roche announcement, Avant and Ainnova Tech shared that they are also working on advancing Ainnova's proprietary low-cost retinal camera, which will be used for fundus photography, and seamlessly packaged together with Ainnova's Vision AI software platform for commercialization.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Other recent industry developments and happenings in the market include:
NVIDIA Corporation (NASDAQ: NVDA), the world leader in accelerated computing, recently announced that global pharmaceutical and techbio industry leaders, academic pioneers and AI researchers are adopting the open-source NVIDIA® BioNeMo™ Framework to advance drug discovery and accelerate molecule design.
"The convergence of AI, accelerated computing and expanding datasets offers unprecedented opportunities for the pharmaceutical industry, as evidenced by recent Nobel Prize wins in chemistry," said Kimberly Powell, vice president of healthcare at NVIDIA. "To help unravel the complexities of biological systems, we've introduced the open-source BioNeMo Framework, which will enable researchers worldwide to accelerate the development of life-saving treatments."
Amazon.com, Inc. (NASDAQ: AMZN), through its subsidiary Amazon Web Services, Inc. (AWS), recently announced that XtalPi, a leading global technology company that combines artificial intelligence (AI) and robotics to drive the discovery of medicine and innovative materials, has selected AWS as its strategic cloud provider. XtalPi uses AI, quantum physics, and robotics to drive innovation in life sciences, chemistry, and new materials. Using AWS, XtalPi helps hundreds of companies, including 16 of the world's top 20 pharmaceutical companies, expedite drug discovery and development, ensure data security and privacy compliance, and enhance their success rates in developing promising new therapies for patients.
"AWS's security and scalability allow XtalPi to develop cloud-based platforms that enhance the efficiency of drug research for leading pharmaceutical companies worldwide," said Deepak Nair, director, Healthcare and Life Sciences at AWS. "AI-driven workflows are poised to transform the rate at which we can move through the drug-discovery process, driving new therapy breakthroughs with lower development costs and faster delivery of lifesaving treatments."
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced publication of its study, "Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer," in JAMA Network Open.
Tempus studied over 5,500 advanced NSCLC patients and found that using both RNA and DNA sequencing identified significantly more actionable genetic variants than DNA testing alone—boosting detection by over
"This large study underscores the importance of using both RNA- and DNA-based comprehensive genomic profiling as a standard of care in advanced NSCLC, and more broadly in solid tumors," said Halla Nimeiri, MD, Chief Development Officer at Tempus. "By integrating RNA and DNA sequencing, we can detect a wider range of actionable alterations that might otherwise go undetected by DNA testing alone. This combined approach enhances clinicians' ability to provide more personalized treatment options for patients."
CONTACT:
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.
View original content:https://www.prnewswire.com/news-releases/healthcare-executives-embrace-generative-ai-to-boost-patient-outcomes-302330485.html
SOURCE
FAQ
What is the projected size of the Global AI Healthcare Market by 2030?
What percentage of healthcare executives report positive ROI from GenAI?
What is the purpose of Avant Technologies' pilot program with Roche?
What percentage of Costa Rica's adult population is affected by diabetes?
Which markets are targeted for expansion of the Avant-Roche pilot program?
